|
|
 |
|
Viewing report
|
|
|
|
Medicated Skin Products Market in Middle East and Africa to 2014 (OTC Healthcare)
Datamonitor, Feb 2011, Pages: 20
Introduction
This databook provides key data and information on the Medicated Skin Products Market in Middle East and Africa (OTC Healthcare). This report is a comprehensive resource for market, category and segment level data including value, volume, distribution share and company & brand share. This report also provides expenditure and consumption data for the historic and forecast periods.
Scope
-Market,category and segment level information on value, volume, and expenditure & consumption, with historic (2003-2008) and forecast (2009-2013) data
-Category level company and brand share as well as distribution share information for 2007 and 2008
Highlights
The medicated skin products category was valued at $264.4m in 2009, representing a CAGR of 5.6% since 2004.
By the end of 2014, the medicated skin products category will be worth $330.9m, with an expected CAGR of 4.6% between 2009 and 2014.
The medicated skin products market was led by anti-bacterials (representing 30.5% of the total value) followed by anti-fungals and acne treatments, with a 21.6% and 18.7% market share, respectively. Disinfectants and other medicated skin products constitute the remaining segments with a 16.8% and 12.4% market share, respectively.
GlaxoSmithKline Plc is the market leader with a 22.6% share of the market.
Reasons to Purchase
-Develop business strategies by understanding the quantitative trends within the Medicated Skin Products Market in Middle East and Africa (OTC Healthcare)
-Design effective marketing and sales strategies by identifying key market categories and segments
-Identify key players within the market to plan lucrative M&A, partnerships and agreements
|
|
|
|
